


3SBio Inc.

**Merrill Lynch Global Pharmaceutical,
Biotechnology & Medical Device
Conference**

David Chen, VP of Business Development

February 5, 2008



Company Overview




3SBio Inc. is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China


- Therapeutically focused in oncology and nephrology markets
- 6 marketed products and 6 pipeline products under development
 - EPIAO, the flagship product, is the No.1 EPO product in Chinese market since 2002*
 - TPIAO, the first protein-based TPO therapeutic product approved in Chinese market
 - Multiple late-stage development programs
- Compelling revenue and profit growth
 - 3 Year ended 2006 net revenue CAGR: 20.5%
 - YoY net revenue growth of 57.3% for third quarter 2007
 - YoY Net Income Growth of 151.4% for third quarter 2007
- Company Facts:
 - Founded in 1993
 - Headquarter & manufacturing facilities: Shenyang
 - Sales headquarter: Beijing
 - Employees: 374 (as of September 30, 2007)
 - NASDAQ IPO on February 7, 2007
 - A total of 21,726,308 ADSs and 152,084,155 common shares were outstanding*
 - 39% public float, include 8,452,140 ADSs and 59,164,980 common shares*
 - Investor information at: www.3SBio.com




Cherish Life



Care for Life




Create Life



Established Nationwide Sales and Marketing Network

We currently distribute our products in 18 provinces and the key major cities throughout China



We are executing on our strategy to grow our sales and marketing infrastructure to meet China's rapidly growing demand for our products

Proven Research and Development Capabilities



Proven Track Record of Product Development & Commercialization

- Successfully developed and commercialized four protein-based therapeutics in China to date
- Proven ability to identify and in-license complementary product opportunities, which our sales force could effectively market and grow sales
- Market driven product development effort with the goal of addressing large markets with significant unmet medical needs in oncology and nephrology

Highly experienced R&D professionals

- 20 research personnel and medical professionals, 7 with advanced degrees and many with extensive experience in the healthcare and biotech research fields

Productive working relationship with the SFDA

- Our productive working relationship with the SFDA is critical when seeking regulatory approvals for new therapeutics in China

Manufacturing and Facilities Overview



- State-of-the-art facility covering 3,000 square meters including a 1,600 square meter clean room
- cGMP certified manufacturing facility and voluntary applications of European Pharmacopoeia standards
- Composed of three departments including mammalian cell genetic engineering, bacterial genetic engineering, and formulation divisions
- High-end name brand equipment including bioreactors, centrifuges, chromatography systems and lyophilizers
- Significant capacity to accommodate substantial growth from key products
 - Phase I of the new plant is expected to complete by the end of 2007
 - Upgrade of other facilities to be EMEA compliance is expected to be near completion in 2008
- Received the government award for R&D and manufacturing capability
 - “Model Manufacturing Base” – awarded by the Ministry of Science and Technology of the People’s Republic of China





Key Revenue Drivers – EPIAO & TPIAO



9-Month 2006

9-Month 2007





■ EPIAO
 ■ TPIAO
 ■ Intefen
 ■ InLeusin
 ■ Iron
 ■ Export
 ■ Others




EPIAO – Steady Revenue and Volume Growth



REVENUE (RMB Million)



EPO VOLUME (VIALS '000)






* source: IMS Health

EPIAO – Continuing to lead the Market



EPIAO (益比奥) has been the No. 1 EPO product on the market in both units sold and revenues since 2002



TPIAO – Accelerating Year Over Year Growth




3Q07 TPIAO Highlights

- Newest in-house developed product and the fastest growing product in our portfolio
- US\$1.9 million in 3Q07 sales : + 171.6% year-over-year increase
- 25.3% of total sales at the end of 3Q07, up from 14.6% for 3Q06
- Phase III trial for treatment of ITP on schedule

TPIAO Revenue 2007


USD millions



Distributing our Products to Developing Countries all over the World



We currently export EPIAO, Interferon, Inleusin (Interleukin), and Tietai to a number of developing countries




- Domestic Market
- 3SBio Export Countries
- Target Export Countries in Registration
- New Export Licenses 2006

2006/7 GMP approval for:

- Sri Lanka (March)
- Trinidad & Tobago (July)
- Republic of Yemen (August)
- Guatemala (September)
- Colombia (November).
- Pakistan (3Q 2007)

Export Sales (as of 3Q 2007)

- Approximately 5.1% of Total Revenues







Export Strategy

3SBio Today - Replicate China model in adjacent SE Asia developing nations under penetrated by international players in EPO


Future Opportunities - Focus on biosimilars and open up opportunities in European markets upon receiving EMEA compliance for new and upgraded production facilities

Enhanced Operational Efficiency and a Track Record of Growth and Profitability





A Focused Strategy To Drive Growth And Profitability





Investment Highlights

1

The Leading Biotechnology Company Built on a Solid Operational Foundation in the Most Rapidly Growing Pharmaceutical Market



Nationwide Sales, Marketing, and Distribution Network



Proven Research and Development Capabilities and Deep Pipeline of Product Candidates



High-quality, Proprietary Manufacturing Processes With Significant Cost Advantages



Experienced and Market Oriented Management Team

2

Strong Financial Performance with Growth and Profitability


3

Synergistic Portfolio of Marketed Products and Late Stage Pipeline with Leading Market Share and Exclusivity in Key Market Segments

4

Clear and Focused Growth Strategy





Thank You

